Thrombosis And Hemostasis Biomarkers Global Market Report 2026

Thrombosis and hemostasis biomarkers are biological indicators that offer insights into blood clot formation and the mechanisms that regulate bleeding. These biomarkers assist in assessing the balance between coagulation and clot breakdown, making them essential for evaluating vascular health and diagnosing coagulation-related disorders.

The main products associated with thrombosis and hemostasis biomarkers include reagents and consumables, as well as analyzers. Reagents and consumables consist of critical chemical substances and disposable laboratory materials such as assay kits, buffers, calibrators, and control solutions that are used to detect, measure, and analyze biomarkers related to clotting and bleeding conditions. These biomarkers are assessed using various tests, including D-dimer, antithrombin III, plasminogen, soluble fibrin, factor VIII, prothrombin time (PT), activated partial thromboplastin time (APTT), and others. They are applied across multiple clinical areas such as cardiovascular diseases, neurological disorders, oncology, pregnancy-related conditions, and orthopedic procedures, and are utilized by end users including hospitals, diagnostic laboratories, pharmaceutical companies, academic institutions, and home healthcare settings.

Tariffs have affected the thrombosis and hemostasis biomarkers market by increasing the cost of imported analyzers, reagents, and calibration materials. Segments such as fully automated coagulation analyzers and specialized immunoassay kits are most impacted, particularly in regions like Asia-Pacific and Europe where imports constitute a significant portion of supply. The tariffs have led to higher production costs and slowed expansion in some regions. Positively, tariffs are driving local manufacturing, innovation in reagent formulations, and investment in domestic diagnostic capabilities.

The thrombosis and hemostasis biomarkers market research report is one of a series of new reports from The Business Research Company that provides thrombosis and hemostasis biomarkers market statistics, including thrombosis and hemostasis biomarkers industry global market size, regional shares, competitors with a thrombosis and hemostasis biomarkers market share, detailed thrombosis and hemostasis biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the thrombosis and hemostasis biomarkers industry. This thrombosis and hemostasis biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The thrombosis and hemostasis biomarkers market size has grown strongly in recent years. It will grow from $5.17 billion in 2025 to $5.56 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to limited availability of coagulation biomarkers, reliance on manual and semi-automated analyzers, increasing prevalence of cardiovascular disorders, growing diagnostic laboratory infrastructure, rising awareness of thrombosis and hemostasis disorders.

The thrombosis and hemostasis biomarkers market size is expected to see strong growth in the next few years. It will grow to $7.37 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to technological advancements in fully automated analyzers, increasing adoption of poct coagulation devices, rising investment in personalized medicine, expansion of pharmaceutical and diagnostic research, development of novel biomarkers for early disease detection. Major trends in the forecast period include growing adoption of advanced coagulation analyzers, rising demand for point-of-care testing solutions, increased focus on early detection of cardiovascular disorders, expansion of diagnostic reagents and immunoassay kits, integration of biomarker testing in personalized medicine.

The growing demand for precise and targeted therapies is expected to propel the growth of the thrombosis and hemostasis biomarkers market going forward. Precise and targeted therapies involve advanced treatment approaches that focus on the specific molecular and genetic features of a patient's disease, with the goal of improving treatment effectiveness while reducing unwanted side effects. The demand for such therapies is increasing due to expanding knowledge of genetic and molecular disease variations, which enables more personalized treatment strategies that enhance clinical outcomes and minimize adverse reactions. This demand supports the thrombosis and hemostasis biomarkers market by driving the development of highly accurate diagnostic tools capable of identifying specific biomarkers, allowing for better-targeted therapies for clotting disorders and improved patient outcomes. For instance, in March 2024, according to Novotech, an Australia-based contract research organization (CRO), among the 217 oncology therapies approved by the U.S. Food and Drug Administration by the end of 2023, 43% were categorized as precision oncology treatments, with 78 incorporating biomarkers detectable through deoxyribonucleic acid (DNA) or next-generation sequencing (NGS). Therefore, the growing demand for precise and targeted therapies is driving the growth of the thrombosis and hemostasis biomarkers market.

Major companies operating in the thrombosis and hemostasis biomarkers market are concentrating on developing advanced solutions such as automation integration to streamline laboratory workflows and enhance testing accuracy. Automation integration in clinical laboratories refers to the implementation of connected automated systems, instruments, and robotic technologies that carry out laboratory testing processes with minimal manual involvement. For example, in April 2024, Siemens Healthcare, a Germany-based medical technology company, in collaboration with Sysmex Corporation, a Japan-based medical technology company, launched a combined portfolio of hemostasis testing solutions for laboratories. This portfolio includes a broad range of established instruments and assay kits designed to support diagnostic testing for bleeding and clotting disorders, enabling dynamic sample routing with automated reflex testing. These capabilities help reduce turnaround times and increase testing throughput without requiring additional staff. Furthermore, automation supports centralized control and real-time monitoring, facilitating intelligent workflow management, integrated quality control, and optimized resource utilization.

In February 2024, Procuritas Capital Investors, a Sweden-based private equity firm, acquired Precision BioLogic (PBI) and Affinity Biologicals for an undisclosed amount. This acquisition aims to strengthen Procuritas' presence in the rapidly growing thrombosis and hemostasis diagnostics market by leveraging Precision BioLogic's FDA-cleared reagents, plasma-based products, and strong research and development capabilities, along with Affinity Biologicals' custom assay services, to capitalize on global healthcare trends. Precision BioLogic (PBI) is a Canada-based provider of diagnostic products for blood coagulation disorders, while Affinity Biologicals is a Canada-based manufacturer of products used in thrombosis and hemostasis research and diagnostics.

Major companies operating in the thrombosis and hemostasis biomarkers market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton Dickinson and Company (BD), Mayo Clinic Laboratories, bioMerieux S.A., Beckman Coulter Inc., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., ARUP Laboratories, HORIBA Ltd., Werfen S.A., Pathkind Diagnostics Pvt. Ltd., Diagnostica Stago, Agilus Diagnostics, Helena Laboratories Corporations, Cleveland Clinic Laboratories, Diazyme Laboratories Inc., Biomedica Diagnostics Inc., Atlas Medical GmbH

North America was the largest region in the thrombosis and hemostasis biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thrombosis and hemostasis biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the thrombosis and hemostasis biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The thrombosis and hemostasis biomarkers market consists of revenues earned by entities by providing services such as clinical laboratory testing services, patient risk assessment services, disease monitoring services, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The thrombosis and hemostasis biomarkers market also includes sales of clot waveform analysis kits, microfluidic coagulation testing devices, and factor assay kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Thrombosis And Hemostasis Biomarkers Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses thrombosis and hemostasis biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for thrombosis and hemostasis biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The thrombosis and hemostasis biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Reagents And Consumables; Analyzers
• 2) By Test Type: D-Dimer; Anti-Thrombin III; Plasminogen; Soluble Fibrin; Factor VIII; Post-Thrombin (PT); Activated Partial Thromboplastin Time (APTT) Test; Other Test Types
• 3) By Application: Cardiovascular Disorders; Neurological Disorders; Oncology; Pregnancy-Related Disorders; Orthopedic Procedures
• 4) By End User: Hospitals; Diagnostics Laboratories; Pharmaceutical Companies; Academic Institutions; Home Healthcare Settings
• Subsegments:
• 1) By Reagents And Consumables: Coagulation Reagents; Control And Calibration Materials; Immunoassay Kits
• 2) By Analyzers: Fully Automated Coagulation Analyzers; Semi-Automated Coagulation Analyzers; Point-Of-Care Coagulation Devices
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Siemens Healthineers AG; Becton Dickinson and Company (BD); Mayo Clinic Laboratories; bioMerieux S.A.; Beckman Coulter Inc.; QuidelOrtho Corporation; Bio-Rad Laboratories Inc.; ARUP Laboratories; HORIBA Ltd.; Werfen S.A.; Pathkind Diagnostics Pvt. Ltd.; Diagnostica Stago; Agilus Diagnostics; Helena Laboratories Corporations; Cleveland Clinic Laboratories; Diazyme Laboratories Inc.; Biomedica Diagnostics Inc.; Atlas Medical GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.